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Summary 
The vascular cell adhesion molecule 1 (VCAM-1) is a 110-kD  member of the immunoglobulin 
gene superfamily expressed on the surface of interleukin 1/$- or tumor necrosis factor a  (TNF)- 
stimulated endothelial cells. The cell surface protein functions as an inducible adhesion receptor 
for circulating mononuclear leukocytes and some tumor cells. We have previously characterized 
the genomic organization of the VCAMI gene and described its chromosomal localization. In 
this report, the promoter of the VCAM1 gene is characterized. New transcription of the VCAMI 
gene occurred when endothelial cells were treated with TNF. Fusion plasmids containing the 
5' flanking sequence of the  VCAM1  gene and the chloramphenicol acetyltransferase reporter 
gene were used to identify c/s-acting sequences that direct the cytokine-induced transcription. 
When transfected into bovine aortic endothelial cells, constructs containing 755 bp of the 5' 
flanking sequence were induced by TNE Within the cytokine-responsive region of the core promoter 
were functional NF-rB and GATA elements. Upstream of the core promoter, the VCAM1  5' 
flanking sequence contained a negative regulatory activity. NF-rB-mediated activation of VCAM1 
gene expression may lead to endothelial expression of a mononuclear leukocyte adhesion molecule 
associated  with initial events in the development of an atherosclerotic lesion. 
V 
ascular cell adhesion molecule 1 (VCAM-1) 1 was first 
identified as an adhesion molecule induced on endothelial 
cells by inflammatory cytokines (IL-1 and TNF) or LPS (1, 
2). The molecule binds cells expressing the integrin, very late 
antigen 4  (VLA-4),  such as monocytes, T  and B lympho- 
cytes, basophils,  and eosinophils, but  not neutrophils  (3). 
VCAM-1 is thought to participate in the recruitment of these 
cells from the bloodstream to sites of inflammatory responses. 
For example, VCAM-1 is upregulated on endothelium of post- 
capillary venules during rejection of cardiac allografts (4). Ar- 
terial expression of VCAM-1 is found in experimental models 
of atherosclerosis in the rabbit.  The rabbit homologue of 
VCAM-1 is expressed locally on arterial endothelium over- 
lying early foam cell lesions in dietary and heritable hyper- 
cholesterolemia (5). In addition to inflammatory and immune 
responses, VCAM-1 may participate in metastasis by facilitating 
adherence of VLA-4-expressing  tumor  cells  to  cytokine- 
activated endothelium (6).  VCAM-1 may play a role in B 
cell development since it is constitutively expressed on follic- 
1 Abbreviations used in this  paper: BAEC, bovine aortic endothelial cells; 
ELAM 1, endothelial-leukocyte  adhesion molecule 1; ICAM-1, intraceUular 
adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1; VLA-4, 
very late antigen 4. 
ular dendritic cells in normal human lymph nodes (7) and 
on bone marrow stromal cells in the mouse (8).  VCAM-1 
can also activate human T cells in conjunction with antibodies 
defining the TCtL (9-11).  This suggests that the VCAM-1/ 
VLA-4 pathway mediates signal transduction as well as cel- 
lular adhesion. 
VCAM-1 was originally cloned from endothelial cells and 
was shown to contain six Ig domains (1). Subsequent anal- 
ysis (12-14) revealed that a seven-Ig domain form is the pre- 
dominant species made by endothelial cells. The new Ig do- 
main,  designated domain 4,  is  strikingly homologous  to 
domain 1. mAb blocking studies (15), as well as experiments 
with chimeric constructs in which domains of VCAM-1 were 
replaced with analogous regions of intracellular adhesion mol- 
ecule 1 (ICAM-1) (16), suggest that the seven-domain form 
contains two functional VLA-4 binding sites,  whereas the 
six-domain form has one binding site. Structural analysis of 
the VCAM1 gene proves that the two transcript forms of 
VCAM1 containing six or seven domains are derived by al- 
ternative mRNA splicing (17). In an effort to further define 
the mechanism of cytokine inducibility, as well as the ele- 
ments of the gene required for maintaining a cell type-re- 
stricted pattern of expression, a functional study of the pro- 
moter region of the VCAMI  gene was undertaken. 
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Isolation  and  Culture  of  Bovine  Aortic  Endothelial  Cells 
(BAEC).  BAEC were isolated and maintained in culture using 
modifications of previously described procedures (18). Aortae were 
transported on ice in DME supplemented with calf serum (10%; 
vol/vol), penicillin (200 U/ml), and streptomycin (200/zg/ml). After 
rinsing once in fresh cold transport media, adventitia was removed 
and the ends were trimmed. The aorta was slit lengthwise and placed 
in an empty, sterile,  150-ram petri dish, lumen side up.  The lu- 
minal surface was covered with 5 mg/ml dispase (Bacillus polymyxa 
grade II; Boehringer-Mannheim Biochemicals,  Indianapolis,  IN) 
in DME supplemented with 5% calf serum. The surface was kept 
moist by reapplication of the dispase solution. After 15 and 30 rain, 
the surface was wiped with a sterile cotton swab. Each swab was 
immersed and shaken in 20 ml of DME supplemented with 10% 
calf serum, penicillin  (100 U/ml), and streptomycin (100/~g/ml). 
After centrifugation for 5 min at 650 g  at 4~  the pellet was 
resuspended in 10 ml of DME supplemented with 10% FCS, gluta- 
mine, and antibiotics,  and plated onto a 100-ram tissue culture dish 
coated with gelatin. Dishes were coated by covering the surface 
with 2% gelatin (Sigma Chemical Co., St. Louis, MO), removing 
the excess, and allowing the plates  to air dry. Cells were grown 
at 37~  in humidified 5%  COs and maintained in DME,  sup- 
plemented with 10% FCS, glutamine,  penicillin, and streptomycin, 
as described earlier (18). When cultures reached confluence (5-7 d), 
each 100-mm dish of cells was subcultured by trypsin dissociation 
and replated into a 150-cm z flask. At confluence,  the flask of cells 
was subcultured 1:2. Confluent cultures in the two 150-cm  ~ flasks 
of cells were subcultured into 24-30 100-mm tissue culture dishes 
and used for transfection. Further passage of BAEC in culture dimin- 
ishes responsiveness  of the cells to cytokine (H. J. Palmer and T. 
Collins, unpublished data). For experiments on cytokine induction, 
cells were exposed to recombinant human TNF-c~ (Genentech, San 
Francisco, CA) at a final concentration of 200 U/ml in complete 
media. COS and HeLa cells were originally obtained from the Amer- 
ican Type Culture Collection (Rockville,  MD), maintained in the 
same media, and were passaged every 3-5 d. Human umbilical vein 
endothelial cells were isolated  and maintained in culture as de- 
scribed (19). 
DNA Sequencing.  Nucleotide sequence was determined by the 
dideoxynucleotide chain termination method with modified T-7 
polymerase (United States Biochemical Corp., Cleveland, OH) and 
c~-[3sS]dATP. Oligonudeotide primers were synthesized on a oli- 
gonucleotide synthesizer (381A; Applied Biosystems,  Inc., Foster 
City, CA) and used without purification. 
Production of a 5' Deletion Series of the VCAM1 Promoter and Con- 
struction of Chloramphenicol Acetyltransferase Reporter Plasmids.  A 
nested series of 5' deletions was generated. A 2,195-bp fragment, 
designated Ffl, which extends 28 bp downstream of the transcrip- 
tional start site, was created by restriction enzyme digestion of a 
2.8-kb human genomic clone of VCAMI (17) in pBluescript with 
SphI and BglI. Smaller constructs were generated by PCR using 
the same VCAM1 genomic clone as a template. A common 3' primer 
(R1) at + 42 bp from the transcriptional start site and five different 
5' primers were utilized to amplify the following regions:  -755 
(designated  F0),  -518 (F1),  -258 (F2),  -98 (F3), and  -44 (F4) 
(Figs.  1 and 3 A). The ends of the Sphl-BglI fragment and the 
PCR-generated fragments were filled using the Klenow fragment 
of DNA polymerase I and blunt end ligated (20) into the Sinai 
site of the reporter plasmid pCAT3 (21). The PCIL fragments were 
phosphorylated by polynucleotide kinase before blunt end ligation 
into the SmaI site of pCAT3. Site-directed mutants were obtained 
from PCR reactions using the 3' primer described above and the 
following 5' primers, which altered the underlined target sites by 
creating noncomplementary transversion mutants (i.e., G to T and 
C to A, and the reverse): FIM (AP-1) 5'-GAAGTTATGGTGTCC- 
CTTTTTTAAAAAAGTCAGGCTCAAAAG-Y;  F2M  (GATA) 
5'-ATGTCGACCCTTTCGATTTCCAGTAAATCGAGCCTTT- 
TGGAGTC-Y; F3M (NF-KB) 5'-TAAACTTTTTTCCCTGGC- 
TCTGCCCTGGGTTTCCCCTTGAATTTATTTAAATCC-Y. 
F0dNF was constructed from two separate amplification products; 
an 86-bp fragment generated from F4 and the reverse primer R1, 
and  a  714-bp  fragment  containing  a  mutated  NF-KB site  and 
F3M-RP (GGATTTAAATAAATTCAAGGGGAAACCCAGGG- 
CAGAGCCAGGGAAAAAAGTTTA). Both fragments were filled 
in with the Klenow fragment of DNA polymerase 1 and phos- 
l~horylated with polynucleotide kinase before blunt end ligation. 
The ligated product was then subjected to a second round of PCR 
with primers F0 and R1 to generate an 800-bp amplification product. 
The PCR. amplification product was ligated into pCAT3 as de- 
scribed  above. The DNA sequence  of each construct was deter- 
mined to confirm the primary structure. 
Transient Expression of VCAM-I  Promoter CAT Reporter Con- 
structs.  Subconfluent  BAEC,  HeLa,  and  COS  cultures  (106 
ceUs/100-mm culture dish) were transfected with each reporter con- 
struct (20 #g) by a modified calcium phosphate precipitation tech- 
nique  (22).  Relative  transfection ef~ciency  was  determined by 
cotransfection with pTKGH (5/~g), a human growth hormone 
construct. Samples of the medium were assayed for growth hor- 
mone by using a commercially available RIA kit (Nichols Institute 
Diagnostics,  San Juan Capistrano,  CA). After transfection,  cultures 
were washed twice with HBSS. Complete media with or without 
cytokine were replenished.  Cells were harvested 48 h after trans- 
fection by trypsin dissociation, centrifuged (650 g for 5 rain), washed 
once in PBS, and resuspended  in 0.20 ml of 0.25 M Tris-HC1 (pH 
7.8) with 10/~g/ml aprotinin (Sigma Chemical Co.). Cells were 
lysed by sonication and one freeze-thaw cycle. Supernatants con- 
taining the cell extracts were obtained after centrifugation for 10 
min at 14,000g and stored at -20~  Transfection of each VCAMI 
promoter-CAT reporter construct was performed in duplicate for 
each experiment and the experiments were repeated at least three 
times using at least two independent plasmid preparations.  Each 
experiment included a negative control, the promoterless plasmid, 
pCAT3, and a positive control, CMV-CAT. 
Cotransfection of  a GATA-2 Expression Plasmid.  To assay for trans- 
activation of the GATA site, 15/zg of a GATA-2 expression plasmid 
(pXM-h-GATA2,  a generous gift ofDrs. D. Wilson and S. Orkin, 
Children's Hospital, Harvard Medical School), 15/~g CAT reporter 
construct, and 5 #g pTKGH were cotransfected into subconfluent 
HeLa cells using the calcium phosphate precipitation technique de- 
scribed  above. 
Chloramphenicol Acetyltransferase Assay.  Conversion of radiola- 
beled acetyl-coenzyme  A to acetylated chloramphenicol  was assayed 
by the two-phase fluor diffusion technique (20). For each sample, 
15-30/~1 of cell extract was incubated at 65~  for 15 min to inacti- 
vate endogenous transacetylases. The assay was performed in a reac- 
tion mixture of 1.25 mM chloramphenicol (Sigma Chemical Co.), 
125 mM Tris HC1 (pH 7.8), and 0.1 #Ci of [3H]acetyl coenzyme 
A (DuPont Co., Wilmington, DE) in a reaction volume of 0.200 
ml. The reaction mixture was overlaid with 5 ml of water-immiscible 
scintillation fluid (Econofluor; DuPont Co.) and incubated at 37~ 
for 2 h.  The activity of the 3H-acetylated  chloramphenicol was 
measured on a scintillation counter (Rackbeta; LKB Instruments, 
Gaithersburg, MD). 
1584  VCAMI  Promoter Nuclear Run-OffAssay.  Nuclei from 5-8  x  107 low-passage 
confluent human umbilical vein endothelial cells were utilized for 
nuclear run-off assays (23). Unstimulated cells and cells treated with 
200 U/ml of TNF for 2 h were analyzed. Cells were washed twice 
with PBS, harvested by scraping, and centrifuged at 650 g for 5 
min. The cell pellet was resuspended in 1 ml of 0.01 M Tris-HC1 
(pH 8.4), 1.5 mM MgCI2, and 0.14 M NaCI, and lysed by the ad- 
dition of 5% NP-40. Progress of lysis was monitored by trypan 
blue exclusion. Nuclei were obtained by centrifugation at 650 g 
for 1 min and were washed twice in 0.02 M Tris (pH 8.0), 20% 
glycerol, 0.14 M KC1, 0.01 M MgC12, 1 mM MnCI2, and 14 mM 
2-ME. Nascent transcripts were radiolabeled for 30 min at 30~ 
in 100 #1 of this buffer supplemented  with 0.125 mCi c~-[3Zp]rUTP 
(New England Nuclear, Boston, MA) and the remaining three 
ribonucleotides (Pharmacia Fine Chemicals, Piscataway, NJ) at a 
final concentration of 1.0 mM. Nuclei were lysed in 1.75 ml of 
4 M guanidine  isothiocyanate,  0.25 M sodium citrate, 0.5% n-lauryl 
sareosine, and 0.1 M B-ME. Chromosomal DNA was sheared by 
passage 10 times through a 22-gauge needle. Labeled RNA was 
recovered by centrifugation through 2.5 ml of 5.4 M CsC1 and 
0.025 M sodium acetate at 36,000 rpm for 16 h in a rotor (SW 
41; Beckman Instruments,  Inc., Palo Alto, CA). Labeled RNA 
pellets were washed with 70% ethanol and resuspended in 200 #1 
of 100 mM Tris/10 mM EDTA buffer. Limited alkaline hydrolysis 
was achieved with the addition of 40 #1 1 M NaOH and incuba- 
tion on ice for 10 min, followed by neutralization with 48 #1 of 
1 M Hepes (pH 7.9) and ethanol precipitation. Denatured target 
DNAs (5 #g) consisted of: a human VCAM1 partial cDNA (12), 
human endothelial-leukocyte  adhesion molecule 1 (ELAMI) par- 
tial cDNA (24), rat brain tubulin cDNA (25), and a control plasmid 
pBS. DNAs were heat/alkali  denatured and immobilized  onto nitro- 
cellulose in a slot blot apparatus (Schleicher  & Schuell, Inc., Keene, 
NH). Filters were baked at 80~  for 2 b and prehybridized for 
3 h at 65~  in 10 mM Tris (pH 8.0), 10 mM EDTA, 300 mM 
NaC1, 0.2 mg/ml Ficoll, 0.2 mg/ml polyvinylpyrrolidone, 10 U 
RNAsin, and 0.1 mg/ml boiled salmon sperm DNA. Approxi- 
mately 3  x  106 cpm labeled probe was added to the prehybridi- 
zation mix and hybridized for 48 h at 65~  Filters were washed 
in 2x SSC for 10 min at 37~  followed  by 50 min at 65~  X-Omat 
film (Kodak) was exposed to the wet filters for 36 h at  -70~ 
Electrophoretic  Mobility Shift Assay.  Nuclear extracts were pre- 
pared from ~107 control or 6-h TNF-treated BAEC prepared by 
the method of Schreiber et al. (26). Protein content was assayed 
utilizing the Bradford reagent (Bio-Rad Laboratories, Richmond, 
CA). Double-stranded oligonucleotides containing wild-type and 
mutant sequences of the GATA and NF-KB recognition sequences 
were synthesized  on an automated DNA synthesizer (Applied Bio- 
systems, Inc., Foster City, CA). Mutant sequences were identical 
to those used in the construction of mutant reporter constructs. 
Oligonucleotides used as probes were: GATA, 5'CTTTATCTTT- 
CCAGTAAAGATAGCC~ NF-KK  CCTTGAAGGGATTTCCC- 
TCC;  and a mutated  form,  CCTTGAATTTATTTAAATCC. 
Wild-type sequences were end labeled with "y-[3~P]ATP  and poly- 
nucleotide kinase. Each reaction contained 10 fmol of probe and 
2-4/.*1 (5 #g protein) of nuclear extract. The buffer for GATA 
binding experiments  contained  10 mM Hepes (pH 7.9), 5% glycerol, 
50 mM KC1, 5 mM MgC12, 1.0 mM EDTA, 1 mM dithiothre- 
itol, and 1 #g poly (dI-dC) (Pharmacia Fine Chemicals). NF-KB 
binding reactions were conducted in 50 mM Hepes (pH 7.9), 30% 
glycerol, 50 mM KC1, 10 mM MgC12, 1 mM dithiothreitol, and 
1 #g poly(dI-dC) in a volume of 20 #1. Binding reactions occurred 
at room temperature for 20 re_in. Complexes  were resolved  on 6.0% 
nondenaturing polyacrylamide  gels in 50 mM Tris, 45 mM borate, 
and 0.5 mM EDTA, pH 7.5 (0.Sx TBE buffer). The samples were 
subjected to electrophoresis for 2-3 h at 10 V/cm. Gels were dried 
and autoradiographed at  -70~  overnight. 
Results 
S~t.raI A~l~ ~the VCAM1 ~mot~ ~gion.  l~ous 
structural analysis of the VCAMI gene revealed a single tran- 
scriptional start site 25 bp downstream of  a consensus TATAA 
box (17). Located near the transcriptional initiation site (Fig. 
1) are several sequences that corresponded to previously defined 
elements. The sequence GGGATTTCCC, at  -57 bp, is in 
complete agreement with the consensus sequence  (GGGR 
[C/A/T]TYYCC) for a NF-~cB binding site (27). The struc- 
ture of this site is identical to the functional NF-kB site found 
in the acute phase response element of the angiotensinogen 
gene (28). A second NF-KB-Iike  site (GGGTTTCCC) is found 
15 bp upstream from the consensus site (e.g., reference 29). 
The sequence TTATCTTTCCAGTAAAGATAG, at position 
-255 to  -235, contains one site conforming to the (T/A) 
TATC(T/A)  consensus characteristic of recognition sites for 
members of the recently described  GATA family of DNA 
binding factors (30); the second site contains the TATC core 
element in the opposite direction. The sequence TGACTCA 
at  -490 bp from the transcriptional start site is identical 
to the AP-1  consensus sequence  TGA(C/G)TCA (31). At 
position  -216  is a purine-rich sequence  (GAGGAAAAG) 
that contains the AGGAA core element of an Ets class (32) 
binding site. At position  -724 is an octamer-like sequence 
ACTTGCAT. 
The nucleotide sequence presented here extends the pub- 
lished sequence by 1,649 nudeotides in the 5' direction. Con- 
tained in this upstream sequence were putative binding sites 
for several classes of transcription factors.  Two sites resem- 
bling octamer binding recognition elements were identified 
in the upstream sequence (Fig. 1). The sequence ATTTACAT, 
at  both  -1547  and  -1175,  resembles  the  binding  site 
(ATTTGCAT) for Oct 1 and Oct 2, and is identical to the 
binding site for yeast MATot2 (33-35). Additionally, two Ets 
class binding sites were identified at positions  -976  (AG- 
GAAG) and  -1026  (GAGGAA). 
TNF Treatment of  Endothelial Cells Results in Transc@tional 
Regulation of the VCAM1 Gen~  Nuclear run-offexperiments 
were performed to determine whether the increase in VCAM-1 
expression  in response  to TNF was mediated by changes in 
transcriptional initiation of the gene. Nuclei were isolated 
from untreated and TNF-treated human umbilical vein en- 
dothelial cells. Radiolabeled newly transcribed RNA from 
these nuclear preparations was hybridized to partial VCAM1 
or ELAMI cDNAs, a control tubulin plasmid, and the pBS 
plasmid backbone. As reported previously, transcription of 
the ELAM1  gene was induced by TNF (36).  VCAM1 tran- 
scriptional activity was not detectable in uninduced human 
umbilical vein endothelial cells, but was strikingly increased 
after 2 h of TNF treatment (Fig.  2). No hybridization was 
seen  between  the  endothelial nuclear RNA  and  the pBS 
plasmid alone. Similar results were obtained with BAEC (data 
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GAATTCAAAATGATATTTCAGT~ACAAGGCCAAACCATATTATGTGCTTTATGCTACTAATAAAAAGGTTAAACCGAACAAGTTCAAAGACAAAACT 
CAGTAGTACTTTATTCAGACAGGTTAGTCTAAATCTGTTAACCTTATACTTGCAACTCTGATCATTCATTAATTCTGCAAATTTTAATAAATo~FTTATT 
TTAAGCTAAATGCTGAGATGAAAAAATGAAACCATATGAGTTAGcAAAGTAGAAAATATAGGCATATTAATCAGTAAATGCAGAATGA~A~  ~  ~GCTCCAT 
CAATATGCACTTGTTGTAGTGAGGCCACCGAGGAGGGTGcAATCCTCTCAAcCTGGGAGGAGCAGGTAGGACTTCAGATGTCATCCAACTCAAAGATATA 
GTGAGGGACTTGATCAAACATTTGCCAAGACCACTATGAGTTA•ATGAATAGATTAGGCATTTCTCCAATGTTGCAAGCTTCGAATCATATCCAAACTCA 
GAACAACATAGcTTGGTCATAATGATCCCAAGGATCCTATTG~CCATTGTCTTTGAGCCTCAAAGGAACATATTAAAACTCCATAATACC=  ~ ~ I-=~-=~GATCT 
ATTCTG~%GTT~GTAGTG~~ATGATGACAC~CAC'~TA"~%GGACCTCTc~3TTACTTG'~TAT~.GCTAGTATTTCC'~%TC~g~T 
T~`GATCCCTAGATA'1~'~W~TAC~'~i~%GT~ATAC~ATATATCCCCACACCCTAG~CAGCATCTCC~CTTATTTTTCCCTCCTTGTCT'~TAGTGGG 
AGCCACATCAGTATCC~GAGGAGATCCAG~GCCT~CC~C~GGTAG~ACAGTTATAGATTCCAG~CC'rCAGCTAT~M~CCTTTGTTACAGAGTACA 
~TGTTATATAGTAC~%~TTTAT.~TACACATCCCATTGAGT~'c.'~G~T'~AG~TTTTCrTGTAG~%TTT~.CAGT~I~TTT~ATGCC~T~.~'~ 
ATTATTGCTAGTATTTAGAATTTTCTTCTCC~-TGTAT~.CGTTTATTAT'I~CATTTTTTGTATCCA~T~d~.GT~.TCATGCATTAGATAT`~TAG 
~.GTAGATAC~CAATG~C/~G/~C'~'..~TCCTGACCATGA~AGG~%CT~ATG~TCC~`~T~'~`~'G~G~TAGACCTGCACGTGTTT~T~C~.G'~.~ 
CTATTC~'~TTTCTTTTTGAT~'GC~GCATTTTGC~GGCCTT~7~CTATGTGTGTGCi~c~'CT~.G~CAGTTAGTT~.TTGc~ATTTTTTT~/~G 
~ACTTCACTC`'GG~-`~GG~CATAGAGTT~TTATTGTCC~TTGCCTAT/~.T~%CCTATTAT'~TT~TTTTTT/~CT~2'GTTTGCGGTT~A 
IFo---, 
T•TCA•AGCCCAAGAGATTTGccACTTCAGATGGATTC•ATAcACTTGcATTTAAGTATGcAAAAAAATTCcAATTATC•AGCAATTTAA••AAATTATT 
GGTAAcTTTTcTAAAA•AAAAAAAAATTGTTT•••TTGTTTTGG•AGcAATTTcAGTTAcAGTccTTTA•TTTcTAcTcAAGAAAATAGTTT•AAAAAGT 
FI+IM------ 
T~ATGTTTGTTGCTAAAAGAACTATTTTTATGAATAAATATAAAACTAAGAAGTTATGGTGTCCCTTTTTTAAAAAA~TCAAAAGAAATAACTT 
T 
TTTCCTTTCTCTTGTAAGAGAAAAAAATTAATcTCTTTTAGAATTGCAAACATATTTCCTTGATGGAGAAAATCAATTCACATGGCATAGTCGTTATTTA 
TcCAGTTCAAAAACCAGAGTAGAATTTACTACTCTGTCTCCATTTTTTCTCTCCCCACCCCCTTAACCCACATTGGATTCAGAAAGCTTCATTCTGCAAT 
I+  ...........  F  2 ~---~ 
~AGCATTGTCCTTT&T~'TTTCcAGT~A~CCTTTTGGAGTCGAAGATGAGGAAAAGCcTGTATTTTATAGTCTTGGAAGTGTCTTCTTTTGCCAGG  ::::::::::::::::::::::::  [ F3+3M---~ 
ACAGAGAGAGGAGCTTCAGCAGTGAGAGCAACTGAAGGGGTTAATAGTGGAACTTGGCTGGGTGTCTGTTAAACTTTTTTCCCTGGCTCTGCcC~ 
[F~---~  -i+i  ......... 
~CCTTG~TTTCCCTCCGCCTCTGCAACAAGACCCTTTATAAAGCACAGACTTTCTATTTC  ACTCCGCGGTATCTGCATCGGGCCTCACTGGC 
TTCAGGAGCTGAATACCCTCCCAGGCACACACAGGTGGGACACAAATAAGGGTTTTGGAACCACTATTTTCTCATCACGACAGCAACTTAAAATGCCTGG 
~---R~] 
GAAGATGGTCGTGATCCTTGGAGCCTCAAATATACTTTGGATAATGTTTGCAGCTT 
Figure  1.  5' sequence  of the human VCAM1  gene.  The transcriptional  start site  is designated  -1  and  the TATAA box is underlined.  Locations 
of the reverse primer (R1) and the forward primers used in the construction  of VCAM/CAT chimeras are indicated.  Consensus AP1,  GATA, NF-KB, 
and  the upstream  octamer-like  sites  are boxed.  The 5'  end of the previously  published sequence  is indicated  with an arrow. 
not shown). From these results we conclude  that TNF in- 
duces a rapid increase in  VCAM1  gene transcription. 
Functional Analysis of the VCAM-I  Core Promoter.  A  se- 
ries of deletion mutant constructs was transfected  into BAEC 
to determine whether DNA sequences immediately flanking 
the transcriptional start site of the VCAMI gene were sufficient 
for cytokine-induced  expression in endothelial cells. Fusion 
plasmids containing portions of VCAM1 5' flanking sequence 
(Fig. 3 A),  -2167 (Ffl),  -755 (F0),  -518 (F1), -258 (F2), 
-98  (F3),  or  -44  (F4),  and the CAT reporter gene were 
constructed  and introduced  into low-passage  BAEC.  Each 
Figure  2.  Nuclear  run-off ex- 
periments in human umbilical vein 
endothelial cells, unstimulated or 
induced  with 200 U/m1 human 
TNF-a for 2 h. Target DNAs are 
partial  VCAMI  and  ELAM1 
cDNAs, rat brain tubulin cDNA, 
and control pBS. 
of the Ffl, F0, F1, F2, and F3 VCAM-CAT  constructs was 
induced by TNF (Fig. 3 B), confirming  that the identified 
VCAM1 promoter was cytokine inducible in BAEC. Primer 
extension  analysis confirmed that transcriptional initiation 
was from the correct VCAM1  transcription start site (data 
not shown). The  -2167 chimera (Ffl) had the lowest level 
of reporter gene expression in unstimulated BAEC, equiva- 
lent  to the promoterless pCAT3 control  construct  used in 
the construction  of the reporter chimeras. Basal expression 
of the F0,  F1, or F2 construct in unstimulated  BAEC was 
higher than the Ffl construct (Fig. 3 B). The Ffl construct 
was induced by TNF, but the extent of induction  was less 
than that obtained with constructs with further 5' deletions. 
This suggests  the presence of a negative element(s) or a si- 
lencer(s) outside  the  -755  to  + 42 region  of the  VCAM1 
gene, which suppresses the expression of VCAM1. Treatment 
of cells with TNF overcomes the inhibitory effect of this nega- 
tive element(s)  and activates the promoter.  Transfection of 
the 5' VCAM1 CAT deletion constructs into other cells that 
could  be induced by cytokine  to express VCAM1  revealed 
a similar inverse correlation between the amount of VCAM1 
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Figure 3.  Deletion analysis  of the VCAMI promoter. (A) Schematic diagram of the 5' deletion mutations in the VCAMI upstream regulatory regions. 
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Figure 4.  Analysis of transcrip- 
tional  control  elements  in  the 
VCAM1  promoter.  Reporter 
phsmids containing mutated recog- 
nition  sites (see Materials  and 
Methods) were transfected and as- 
sayed in BAEC (A) and COS cells 
(/3). Results are reported as the ratio 
of CAT activity to human growth 
hormone (CPM/ng/ml). 5' flanking sequence and either basal or induced marker gene 
activity (data not shown).  This suggests that  at least some 
of the negative effect is not cell type specific.  The F0,  F1, 
and F2 deletion constructs showed approximately equivalent 
levels of induced activity after TNF treatment of cells (Fig. 
3 B). The F3 deletion construct shows "~50% of the TNF- 
induced  activity of the F0,  F1,  and F2 constructs.  The F4 
construct  was  not  basally active  and  was  not  induced  by 
cytokine, as expected for a chimera containing only the TATAA 
box and no other upstream  sequences. 
Role of the NF4cB Binding Site in  the  TNF Induction of 
VCAM-I Gene Transcription.  The data presented above sug- 
gest that  TNF-induced  expression of the  VCAM1  gene is 
required in part by 5' flanking sequences present between the 
-258 to  -98 and the  -98 to  -44 regions of the core pro- 
moter. Within this VCAMI minimal promoter region were 
sequences that conform to consensus NF-KB and GATA ele- 
ments.  The NF-KB transcription  factor family is known to 
play a role in cytokine induction  of many genes (reviewed 
in references  27, 29, and 37). To further investigate the role 
of these elements in TNF-induced VCAMI expression, con- 
structs  were generated  that  specifically  altered  these sites. 
Deletion analysis  was used to determine  if the  VCAMI 
NF-KB sequences were a functional promoter element. Block 
mutations of the homologous VCAMI sequence were gener- 
ated in the F3 chimera (F3mA and F3mB).  The sites were 
changed by noncomplementary transversion mutation.  The 
activity of mutant  (F3mB) was compared with that  of the 
wild-type F3 fusion construct in BAEC and COS cells (Fig. 
4, A  and B). Changes in the structure of the consensus NF- 
KB element at  -  57 totally abolished both inducible and basal 
transcription  in either cell type.  Similarly,  specific  changes 
in the upstream NF-t~B site (F3mA) abolished basal and in- 
ducible  transcription.  An  additional  site-directed  mutant, 
F0dNF, contained all of the sequence in the F0 (- 755) con- 
struct except the bases of the 3' NF-KB element. TNF-induced 
reporter gene expression from this deletion construct was ab- 
sent,  suggesting  that  an NF-~cB-like factor binding  to this 
site  is necessary for TNF induction  of VCAMI  gene tran- 
scription.  The pattern of expression of the VCAM1 NF-t~B 
deletions in COS (Fig.  4 B, and data not shown) and HeLa 
cells (data not shown) in uninduced and in TNF-induced cells 
was similar to that  seen with BAEC. These results indicate 
that  at least part  of the mechanism(s)  involved in cytokine 
induction of VCAMI in endothelial cells is functional in these 
nonendothelial  cell types. 
Gel shift  assays were performed to identify nuclear  pro- 
teins specifically recognizing the 3' VCAMI NF-gB element. 
A labeled DNA fragment spanning this region was incubated 
with BAEC extract prepared from control and TNF-treated 
BAEC  in  the  presence  of  specific,  mutated  specific,  or 
nonspecific competitor DNAs (Fig.  5). Two specific DNA- 
protein complexes were observed with extracts from TNF- 
treated endothelial cells. Addition of excess unlabeled DNA 
spanning the NF-KB element of the promoter blocked both 
of the TNF-inducible  DNA-protein complexes. Formation 
of these complexes was not blocked by heterologous compe- 
Figure 5.  Binding  of an endothelial NF-~B-like  factor to the VCAMI 
NF-KB element. Nuclear extracts from uninduced (lane 2) and TNF- 
stimulated BAEC  (lanes  3-6) were  incubated  with 10 fmol  of  hbeled  double- 
stranded oligonucleotide  probe containing the VCAM1 NF-KB  recogni- 
tion site. Competitor oligonucleotides  were  present at 50-fold  molar excess 
and include specific  competitor (lane 4), competitor  with a mutated NF- 
KB binding site (lane 5), and an irrelevant double-strand oligonucleotide 
(lane 6). Specific  DNA-protein  complexes  (arrows);  unbound  free  probe  (F). 
titors, or by a DNA fragment containing a mutated VCAM! 
NF-gB site. These results confirm the importance of this ele- 
ment of the VCAM1 gene in regulation of cytokine induc- 
tion of VCAM-1 and demonstrate that endothelial cells make 
protein(s) capable of binding to this promoter element. The 
nature of these putative NF-IcB family members is under in- 
vestigation. 
Role of  the GATA Sites in TNF Induction of VCAM1 Gene 
Transc@tion.  The data presented above demonstrate that an 
important  element  for  TNF-induced  VCAM1  expression 
is  present  within  the  -258  to  -98  region  of  the  pro- 
moter. Within  this region (-255  to  -235) is the sequence 
TTATCTTTCCAGTAAAGATAG, which contains two puta- 
tive sites: GATA and TATC, characteristic of recognition sites 
for members of the recently described GATA family of DNA 
binding factors (30). To determine if either of these sites plays 
a role in  VCAM1  gene expression, block mutations  of the 
homologous VCAMI sequence were generated in the F2 chi- 
mera.  Each base between nucleotides 253-251 and 239-237 
was changed by noncomplementary transversion mutation. 
The activity of this mutant  (F2m) was compared with the 
wild-type F2 fusion construct in both BAEC and COS cells 
(Fig.  4,  A  and B).  Changes  in the  sequence of the GATA 
elements decreased both basal and TNF-induced transcrip- 
tion  in both  ceil types by '~50%. 
To confirm  a role for GATA factors in the basal and in- 
duced expression of the VCAM1 gene, cotransfection experi- 
ments with  a GATA-2 expression construct  (38) were per- 
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Figure 6.  Transactivation of VCAM1  reporter constructs  by a human 
GATA-2 expression vector. HeLa cells were cotransfected with 15/zg of 
reporter plasmid, 15 #g of the GATA-2  expression plasmid pXM-hGATA, 
and 5 ~g of a normalization plasmid. 
formed.  In  the  presence  of TNF,  transcriptional  activity 
increased  fivefold in  ceils  cotransfected with  the F0 or F2 
VCAMI  reporter  construct  and  the  GATA-2  expression 
plasmid (Fig. 6). Cotransfection of the expression vector with 
a construct bearing a mutant GATA site,  or a 5' deletion of 
the GATA region, decreased the effect. Cotransfection of the 
expression vector backbone plasmid pMT2 had no effect on 
reporter gene transcription.  The GATA expression vector did 
not trans-activate  the promoterless pCAT3 construct;  addi- 
tionally,  there was no  trans-activation  of a human  growth 
hormone gene placed under the transcriptional  control of a 
thymidine  kinase promoter. 
Gel shift  assays were performed  to identify nuclear pro- 
teins specifically recognizing the GATA sequences from po- 
sitions  -  256 to  -  230 of the promoter. A labeled DNA frag- 
ment spanning this region was incubated with BAEC extract 
in the presence of specific and nonspecific competitor DNA. 
A  DNA-protein  complex  was  observed in  the  absence  of 
specific  competitors  (Fig.  7).  Addition  of excess  unlabeled 
DNA  spanning  this region  of the gene blocked formation 
of the labeled DNA-protein complex. Formation of the com- 
plex was not blocked by heterologous competitor (data not 
shown). When a similarly sized oligonucleotide probe con- 
taining  the endothelin  1 promoter GATA  site (38, 39) was 
incubated with the same nuclear extract, a DNA-protein com- 
plex was formed that  comigrated  with  that  seen with  the 
VCAMI  probe (Fig.  7).  From these experiments,  we con- 
clude that a GATA factor acts as a positive regulator of TNF- 
inducible  transcription  of the  VCAM1  gene. 
Together these results suggest that there are at least three 
separate clusters of elements within the VCAMI  5' flanking 
sequence involved in cytokine-induced expression of the gene: 
a negative regulatory element(s), the GATA sites, and the NF- 
KB binding sites. Thus, cytokine induction of VCAM1  gene 
transcription  appears to involve interaction between a com- 
bination of c/s-acting elements and the tram-acting factors that 
interact  with  these elements. 
Figure 7.  Binding of an endothelial GATA-like  factor to the VCAMI 
GATA element. Labeled double-strand oligonucleotide probe containing 
the VCAMI GATA  (lanes I-3) and endothelin 1 GATA  (lanes 4-6) recog- 
nition sites were incubated with nuclear extracts from uninduced BAEC 
(lanes 2 and 3, and 5 and 6). Specific competitor oligonucleotides were 
present at 50-fold molar excess (lanes 3 and 6). Specific  DNA-protein com- 
plexes (arrows); unbound free probe (F). 
The AP1  Site in the VCAMI  Promoter Is Not Required for 
TNF Induction.  AP1 sites have been shown to mediate tran- 
scriptional responses to cytokines such as TNF (40).  Addi- 
tionally, c-fos-c-jun complexes are induced after TNF-mediated 
activation of cultured endothelial cells (41). At  -490 in the 
VCAMI  promoter is the sequence TGACTCA, which is iden- 
tical to the AP1 consensus sequence TGA(C/G)TCA  (31). 
Inspection  of the  sequence flanking  the AP1  core dement 
A(TGACTCA)T reveals a T  3' to the consensus. The func- 
tion of each base pair in the consensus element and the flanking 
sequence on the binding  of c-J~s and c;/un  has been inves- 
tigated  (42).  The presence of the 3'  T  diminishes  in vitro 
binding  of c-J~s and  c;iun  by >75%.  To  test  whether  the 
VCAMI  AP1 site was necessary for the high level of gene 
expression in BAEC, a block mutation was introduced into 
the AP1 site of the F1 construct. The activity of this mutant 
(Flm) was compared with that of the wild-type F1 construct 
in both BAEC and COS cells (Fig.  4, A  and B). Structural 
alteration of the AP1 site had little effect on either basal or 
TNF-induced  reporter  gene expression in BAEC.  A  small 
increase of both basal and inducible expression of CAT was 
observed in COS cells with construct Flm. The F2 deletion 
construct, which deleted the AP1 site (along with 260 bases 
of surrounding  sequence) also had  a similar  small increase 
in CAT activity.  These observations indicate that  the APl 
site in the VCAMI promoter is not necessary for TNF-induced 
transcription.  The AP1 site is not required for efficient VCAM1 
gene expression in endothelial  cells.  In  the B  globin  HSII 
region, erythroid specificity appears to be due to binding of 
a tissue-specific factor (NFE2) to an APlqike site (43). Since 
alteration of the VCAM1  AP1 site had no effect on the ceU 
type specificity of expression (Fig.  4, A  and B), it is unlikely 
1589  Neish et al. that endothelial cells make a lineage-specific  protein that acts 
through the AP1 site in the VCAM1  gene. 
Discussion 
VCAM-1 is a member of the Ig gene superfamily that func- 
tions as an adhesion receptor and a signal transducer to leu- 
kocytes  expressing  the ligand VLA-4. The previously  described 
induction of VCAM-1 protein expression on endothelial cells 
after cytokine treatment (1) was shown here to correlate with 
a similar regulation of transcription initiation of the VCAM1 
gene. The deletion and block mutation experiments define 
two functionally important elements: a pair of GATA sites 
and two NF-xB  sites. These sites in the core promoter of 
the VCAM1 gene are important for the cytokine-induced ex- 
pression of the gene. 
In the VCAM1 promoter, two GATA elements are found 
~10 bp apart in opposite transcriptional  orientation. Anal- 
ysis of other promoters reveals  a similar arrangement of GATA 
sites. The y-globin promoter contains two functional GATA 
elements (CAGATATTTGCATTGAGATAGT)  that are 10 bp 
apart (44). The GATA-1 promoter contains two functional 
GATA recognition elements  (CTGATAAGACTTATCTG) 
that, as in the VCAM1  gene, are placed in opposite  tran- 
scriptional orientation (45). The GATA family of transcrip- 
tion factors is known to interact with other tram-acting  factors. 
Within erythroid-specific promoters, GATA elements appear 
to cooperate with CACCC boxes to direct gene expression 
(30). The analysis of the VCAMI promoter presented here 
suggests that factors binding to the GATA sites and transcrip- 
tion factors recognizing the NF-KB sites may interact  to 
generate full  VCAMI  cytokine responsiveness. 
While GATA elements in VCAM1 promoter are impor- 
tant positive regulators of expression, they cannot be primarily 
responsible for the restricted cell type pattern of VCAM-1 
expression. Two arguments support this idea. First, a diver- 
sity of cells express members of the GATA family of tran- 
scription  factors. The GATA family contains at least three 
members (reviewed in reference 30). Endothelial cells, as well 
as a variety of other cells, express GATA-2 (38). Second, struc- 
tural alterations in the GATA site did not preferentially alter 
the level of VCAM1 expression in endothelial cells (Fig. 4, 
A and B). Additionally, identification of an upstream region 
of the VCAMI promoter that contains a negative element 
suggests that additional regulatory components may be present 
elsewhere in the gene. These regulatory elements may in- 
teract with the GATA binding factor to confer lineage re- 
striction. Such  a model has recently been suggested for platelet 
factor 4 (PF4). In this gene, an upstream tissue-specific si- 
lencer/enhancer element interacts with a GATA site present 
in  the core promoter to  restrict  PF4 gene  expression  to 
megakaryocytes (46). 
Another functional element in the VCAM1 promoter are 
the NF-KB binding sites. NF-KB, a ubiquitously expressed 
transcription  factor, is involved in the increased expression 
of many cytokine-induced  genes (reviewed in references 27, 
29, and 37). Like  VCAM-1, expression  of  ELAM-1 and ICAM- 
1 are upregulated in endothelial  cells  by inflammatory cytokines 
(reviewed in reference 47). Structural analysis of the ELAM1 
and ICAMI genes revealed putative NF-KB binding sites in 
the 5' flanking sequences (48-50).  Deletion analysis of the 
ELAM1 promoter revealed  that cytokine induction of ELAMI 
gene expression required the NF-KB site (36). An NF-KB- 
like factor was induced in cytokine-treated endothelial cells 
that bound to the NF-KB element in the ELAM1 promoter 
(36, 49). However, the nature of the forms of NF-KB binding 
to elements in the promoters of the genes for leukocyte adhe- 
sion molecules remains to be determined. Specificity deter- 
mined by the association of NF-xB components has recently 
been shown to provide a mechanism to selectively regulate 
genes containing NF-KB sites (51). Definition of the forms 
of NF-KB interacting with the promoters of VCAMI  and 
ELAMI genes may help explain the different temporal and 
anatomic patterns of expression of these leukocyte adhesion 
molecules (reviewed in reference 47). 
It is tempting to speculate that NF-KB-mediated activa- 
tion of VCAM-1 expression may play a role in the develop- 
ment of atherosclerosis. Formation of the atherosclerotic le- 
sion involves the adherence and transmigration of circulating 
monocytes into the arterial intima (reviewed in references 52 
and 53). VCAM-1 and ICAM-1 are known to bind mono- 
cytes  in  monolayer  adhesion  assays in  vitro  and  bind 
mononuclear cells in vivo (reviewed in reference 47). Expres- 
sions of  VCAM-1 and ICAM-1 are upregulated in endothelium 
adjacent to early foam cell lesions in the aorta of experimental 
models  of  atherosclerosis.  ICAM-1  expression  has  been 
identified in human atherosclerotic plaques (54). Thus, ex- 
pression of these leukocyte adhesion molecules may be an im- 
portant event in early atherosclerosis (5). Since NF-KB con- 
trols  the  cytokine-induced expression  of these  leukocyte 
adhesion molecules, NF-KB may be important in the initia- 
tion of the atherosclerotic lesion. Consistent  with the pro- 
posal that multiple factors can initiate atherosclerosis  (reviewed 
in references 52 and 53), a variety of signals can activate NF- 
KB (reviewed in references  27, 29, and 37). For example, these 
NF-KB-activating  signals can  emanate  from  cell  surface 
receptors for cytokines (IL-1B, TNF-ot, and -B) or LPS, from 
second messenger pathways, or protein kinase C activation. 
More specifically,  reactive oxygen intermediates are associated 
with the formation of atherosclerosis and have been shown 
to activate NF-KB (55). Additionally, oxidized lipids are in- 
volved in the formation of atherosclerotic lesions (reviewed 
in reference 56), and activate NF-KB (Dr.  Alan Fogelman, 
UCLA School of Medicine, personal communication). Simi- 
larly, viruses such as Herpes virus and cytomegalovirus have 
been implicated in atherosclerosis (57, 58) and these agents 
can activate NF-KB (reviewed  in reference  37). Thus, this tran- 
scriptional mediator is an attractive candidate for linking the 
otherwise seemingly diverse etiologic agents associated with 
atherosclerosis to the expression of a mononuclear-selective 
leukocyte adhesion molecule that has been implicated in the 
initiation of lesion formation. Additionally, endothelial cells 
at sites of developing atherosclerotic lesions are believed to 
have increased expression  of multiple cytokines  (59) and 
1590  VCAM1  Promoter growth  factors  (52).  Since  NF-KB  sites  are  found in  the 
promoters of a variety of relevant  soluble (e.g.,  IL-6, Ib8, 
TNF-ct, G-CSF, GM-CSF, and gro), as well as cell surface 
(e.g., MHC class I and II) mediators, activation of a single 
pleiotropic transcriptional factor like NF-KB in endothelial 
cells could increase expression of multiple pathophysiologi- 
cally relevant  agents. 
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